Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 41 | ECE2016 | Next issue

18th European Congress of Endocrinology

Symposia

Management of Cushing's syndrome

ea0041s13.1 | Management of Cushing's syndrome | ECE2016

New developments in the medical treatment of Cushing’s disease

Feelders Richard

Cushing’s disease (CD), caused by a corticotroph pituitary adenoma, is associated with multi-system morbidity and when untreated or suboptimally treated with an increased mortality. Transsphenoidal adenomectomy is the first choice of treatment for CD. Medical treatment is an option in patients in whom surgery is not successful or not feasible. Medical therapy for CD can be classified into pituitary-directed drugs, adrenal-blocking drugs and glucocorticoid receptor antagon...

ea0041s13.3 | Management of Cushing's syndrome | ECE2016

Rethinking familial adrenal Cushing’s

Lodish Maya

Primary adrenal Cushing syndrome is the result of cortisol hypersecretion mainly by adenomas and, rarely, by bilateral micronodular or macronodular adrenocortical hyperplasia. cAMP-dependent protein kinase A (PKA) signaling is the major activator of cortisol secretion in the adrenal cortex. Many adenomas and hyperplasias associated with primary hypercortisolism carry somatic or germline mutations of genes that constitute part of the cAMP–PKA pathway. We will discuss Cushi...